A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

British Journal of Cancer

Volumn 100, Issue 2, 2009, Pages 366-369

  Descamps, G ^a   Gomez Bougie, P ^a   Venot, C ^b   Moreau, P ^c   Bataille, R ^a   Amiot, M ^a,d  

^a INSERM   (France)

^b SANOFI   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d Team 12   (France)

Author keywords

Bortezomib; CD45; IGF 1 IGF 1R; Multiple myeloma; Translocation (4,14)

Indexed keywords

AVE 1642; BORTEZOMIB; CD45 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN NOXA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 58749086023     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604839     Document Type: Article

References (11)

1. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 91: 1234-1240
2. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P (2005) CD221(IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 90: 706-707
3. Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Collette M, Robillard N, Bataille R, Amiot M (2006) CD45neg but not CD45pos human myeloma cells are sensible to the inhibition of IGF-1 signaling by anti-IGF-1R monoclonal antibody. J Immunol 177: 4218-4223
4. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, Moreau P, Bataille R, Amiot M (2007) Noxa up-regulation and Mcl-1 L cleavage are associated to apoptosis induction by Bortezomib in myeloma cells. Cancer Res 67: 5418-5424
5. Houshmand P, Zlotnik A (2003) Targeting tumor cells. Curr Opin Cell Biol 15: 640-644
6. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51
7. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192
8. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N Harousseau JL, Bataille R (2004) Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 89: 547-551
9. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006b) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113-3120
10. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006a) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57: 33-47
11. Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA (2007) Antibody targeting of the insulin-like growth factor I receptor enhances the antitumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56: 343-357